On the introduction of genetically modified Leishmania outside the laboratory.
Gueiros-Filho
F J
FJ
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115.
Beverley
S M
SM
D000818:Animals; D004351:Drug Resistance / Q000235:genetics; D005786:Gene Expression Regulation; D017125:Genes, Protozoan; D005818:Genetic Engineering; D005819:Genetic Markers; D019868:Kanamycin Kinase; D018320:Leishmania major / Q000187:drug effects / Q000235:genetics* / Q000276:immunology; D010303:Paromomycin / Q000494:pharmacology; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000235:genetics; D016052:Protozoan Vaccines / Q000235:genetics; D014162:Transfection; D014613:Vaccines, Attenuated / Q000235:genetics
D005819:Genetic Markers; D016052:Protozoan Vaccines; D014613:Vaccines, Attenuated; D010303:Paromomycin; D017853:Phosphotransferases (Alcohol Group Acceptor); C063242:hygromycin-B kinase; D019868:Kanamycin Kinase